Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 05-Apr-24 4:55 PM View:  | Tananbaum James B. Director 10% Owner | Kinnate Biopharma Inc. (KNTE) | 03-Apr-24 | Disposition Duplicate | 13,718,300 | -- | -- | (100%) 13.72M to 0 | |
| 05-Apr-24 2:15 PM View: | Foresite Capital Management... 10% Owner | Kinnate Biopharma Inc. (KNTE) | 03-Apr-24 | Disposition | 13,718,300 | -- | -- | (100%) 13.72M to 0 | |
| 05-Apr-24 4:55 PM View: | Meltz Mark A COO General Counsel Secretary | Kinnate Biopharma Inc. (KNTE) | 03-Apr-24 | Disposition | 27,578 | -- | -- | (100%) 27.58K to 0 | |
| 05-Apr-24 4:55 PM View: | Flaherty Keith T. Director | Kinnate Biopharma Inc. (KNTE) | 03-Apr-24 | Disposition | 66,377 | -- | -- | (100%) 66.38K to 0 | |
| 05-Apr-24 4:55 PM View: | Farzan Nima Chief Executive Officer Director | Kinnate Biopharma Inc. (KNTE) | 03-Apr-24 | Disposition | 2,186 | -- | -- | (100%) 2.19K to 0 | |
| 05-Apr-24 4:39 PM View: | Gordon Carl L Director 10% Owner | Kinnate Biopharma Inc. (KNTE) | 03-Apr-24 | Disposition Duplicate | 8,009,730 | -- | -- | (100%) 8.01M to 0 | |
| 05-Apr-24 4:55 PM View: | Krishnamohan Neha Chief Financial Officer | Kinnate Biopharma Inc. (KNTE) | 03-Apr-24 | Disposition | 64,087 | -- | -- | (100%) 64.09K to 0 | |
| 05-Apr-24 4:33 PM View: | Orbimed Advisors LLC Director 10% Owner | Kinnate Biopharma Inc. (KNTE) | 03-Apr-24 | Disposition | 8,009,730 | -- | -- | (100%) 8.01M to 0 | |
| 05-Mar-24 5:00 PM View: | Meltz Mark A COO General Counsel Secretary | Kinnate Biopharma Inc. (KNTE) | 01-Mar-24 | Payment of Exercise | 558 | $2.59 | $1,445.22 | (2%) 28.14K to 27.58K | |
| 05-Mar-24 5:00 PM View: | Williams Richard Thomas Chief Medical Officer | Kinnate Biopharma Inc. (KNTE) | 01-Mar-24 | Payment of Exercise | 558 | $2.59 | $1,445.22 | (< 1%) 68.15K to 67.59K | |
| 05-Mar-24 5:00 PM View: | Krishnamohan Neha Chief Financial Officer | Kinnate Biopharma Inc. (KNTE) | 01-Mar-24 | Payment of Exercise | 1,506 | $2.59 | $3,900.54 | (2%) 65.59K to 64.09K | |
| 05-Dec-23 5:00 PM View: | Meltz Mark A COO General Counsel Secretary | Kinnate Biopharma Inc. (KNTE) | 01-Dec-23 | Payment of Exercise | 541 | $2.25 | $1,217.25 | (2%) 28.68K to 28.14K | |
| 05-Dec-23 5:00 PM View: | Williams Richard Thomas Chief Medical Officer | Kinnate Biopharma Inc. (KNTE) | 01-Dec-23 | Payment of Exercise | 541 | $2.25 | $1,217.25 | (< 1%) 68.69K to 68.15K | |
| 05-Dec-23 5:00 PM View: | Krishnamohan Neha Chief Financial Officer | Kinnate Biopharma Inc. (KNTE) | 01-Dec-23 | Payment of Exercise | 1,459 | $2.25 | $3,282.75 | (2%) 67.05K to 65.59K | |
| 06-Sep-23 5:00 PM View: | Meltz Mark A COO General Counsel Secretary | Kinnate Biopharma Inc. (KNTE) | 01-Sep-23 | Payment of Exercise | 541 | $2.35 | $1,271.35 | (2%) 29.22K to 28.68K | |
| 06-Sep-23 5:00 PM View: | Krishnamohan Neha Chief Financial Officer | Kinnate Biopharma Inc. (KNTE) | 01-Sep-23 | Payment of Exercise | 1,459 | $2.35 | $3,428.65 | (2%) 68.51K to 67.05K | |
| 06-Sep-23 5:00 PM View: | Williams Richard Thomas Chief Medical Officer | Kinnate Biopharma Inc. (KNTE) | 01-Sep-23 | Payment of Exercise | 541 | $2.35 | $1,271.35 | (< 1%) 69.23K to 68.69K | |
| 05-Jun-23 5:01 PM View: | Williams Richard Thomas Chief Medical Officer | Kinnate Biopharma Inc. (KNTE) | 01-Jun-23 | Payment of Exercise | 541 | $4.30 | $2,326.30 | (< 1%) 69.77K to 69.23K | |
| 05-Jun-23 5:00 PM View: | Meltz Mark A COO General Counsel Secretary | Kinnate Biopharma Inc. (KNTE) | 01-Jun-23 | Payment of Exercise | 541 | $4.30 | $2,326.30 | (2%) 29.76K to 29.22K | |
| 05-Jun-23 5:00 PM View: | Krishnamohan Neha Chief Financial Officer | Kinnate Biopharma Inc. (KNTE) | 01-Jun-23 | Payment of Exercise | 1,459 | $4.30 | $6,273.70 | (2%) 69.97K to 68.51K | |
| 10-May-23 5:49 PM View: | Tananbaum James B. Director 10% Owner | Kinnate Biopharma Inc. (KNTE) | 08-May-23 | Private Purchase Duplicate | 1,780,000 | $2.80 | $4,984,000.00 | 15% 11.94M to 13.72M | |
| 10-May-23 5:42 PM View: | Foresite Capital Management... 10% Owner | Kinnate Biopharma Inc. (KNTE) | 08-May-23 | Private Purchase | 1,780,000 | $2.80 | $4,984,000.00 | 15% 11.94M to 13.72M | |
| 08-May-23 5:11 PM View: | Gordon Carl L Director 10% Owner | Kinnate Biopharma Inc. (KNTE) | 05-May-23 | Purchase | 981,023 | $2.82 | $2,766,480.00 | 14% 7.03M to 8.01M | |
| 08-May-23 5:22 PM View: | Orbimed Advisors LLC Director 10% Owner | Kinnate Biopharma Inc. (KNTE) | 05-May-23 | Purchase Duplicate | 981,023 | $2.82 | $2,766,480.00 | 14% 7.03M to 8.01M | |
| 08-May-23 5:22 PM View: | Orbimed Advisors LLC Director 10% Owner | Kinnate Biopharma Inc. (KNTE) | 04-May-23 | Private Purchase Duplicate | 479,909 | $2.75 | $1,319,750.00 | 7% 6.55M to 7.03M | |
| 08-May-23 5:11 PM View: | Gordon Carl L Director 10% Owner | Kinnate Biopharma Inc. (KNTE) | 04-May-23 | Private Purchase | 479,909 | $2.75 | $1,319,750.00 | 7% 6.55M to 7.03M | |
| 02-May-23 10:00 PM View: | Gordon Carl L Director 10% Owner | Kinnate Biopharma Inc. (KNTE) | 02-May-23 | Purchase Duplicate | 338,262 | $2.67 | $903,160.00 | 5% 6.21M to 6.55M | |
| 02-May-23 10:00 PM View: | Orbimed Advisors LLC Director 10% Owner | Kinnate Biopharma Inc. (KNTE) | 02-May-23 | Purchase | 338,262 | $2.67 | $903,160.00 | 5% 6.21M to 6.55M | |
| 02-May-23 10:00 PM View: | Gordon Carl L Director 10% Owner | Kinnate Biopharma Inc. (KNTE) | 01-May-23 | Purchase Duplicate | 716,157 | $2.62 | $1,876,330.00 | 13% 5.49M to 6.21M | |
| 02-May-23 10:00 PM View: | Orbimed Advisors LLC Director 10% Owner | Kinnate Biopharma Inc. (KNTE) | 01-May-23 | Purchase | 716,157 | $2.62 | $1,876,330.00 | 13% 5.49M to 6.21M | |
| 02-May-23 10:00 PM View: | Orbimed Advisors LLC Director 10% Owner | Kinnate Biopharma Inc. (KNTE) | 28-Apr-23 | Private Purchase | 350,749 | $2.55 | $894,410.00 | 7% 5.14M to 5.49M | |
| 02-May-23 10:00 PM View: | Gordon Carl L Director 10% Owner | Kinnate Biopharma Inc. (KNTE) | 28-Apr-23 | Private Purchase Duplicate | 350,749 | $2.55 | $894,410.00 | 7% 5.14M to 5.49M | |
| 03-Mar-23 5:57 PM View: | Meltz Mark A COO General Counsel Secretary | Kinnate Biopharma Inc. (KNTE) | 01-Mar-23 | Payment of Exercise | 638 | $5.21 | $3,323.98 | (2%) 27.92K to 27.29K | |
| 03-Mar-23 5:56 PM View: | Krishnamohan Neha Chief Financial Officer | Kinnate Biopharma Inc. (KNTE) | 01-Mar-23 | Payment of Exercise | 1,721 | $5.21 | $8,966.41 | (2%) 69.1K to 67.38K | |
| 03-Mar-23 5:58 PM View: | Williams Richard Thomas Chief Medical Officer | Kinnate Biopharma Inc. (KNTE) | 01-Mar-23 | Payment of Exercise | 638 | $5.21 | $3,323.98 | (< 1%) 67.93K to 67.3K | |
| 22-Feb-23 2:50 PM View: | Tananbaum James B. Director 10% Owner | Kinnate Biopharma Inc. (KNTE) | 17-Feb-23 | Acquisition (other) Duplicate | 1,100,000 | -- | -- | 10% 10.84M to 11.94M | |
| 22-Feb-23 4:30 PM View: | Gordon Carl L Director 10% Owner | Kinnate Biopharma Inc. (KNTE) | 17-Feb-23 | Grant | 1,100,000 | -- | -- | 27% 4.04M to 5.14M | |
| 22-Feb-23 2:49 PM View: | Foresite Capital Management... 10% Owner | Kinnate Biopharma Inc. (KNTE) | 17-Feb-23 | Acquisition (other) | 1,100,000 | -- | -- | 10% 10.84M to 11.94M | |
| 23-Feb-23 2:16 PM View: | Orbimed Advisors LLC Director 10% Owner | Kinnate Biopharma Inc. (KNTE) | 17-Feb-23 | Grant Duplicate | 1,100,000 | -- | -- | 27% 4.04M to 5.14M | |
| 02-Dec-22 8:00 PM View: | Krishnamohan Neha Chief Financial Officer | Kinnate Biopharma Inc. (KNTE) | 01-Dec-22 | Payment of Exercise | 1,459 | $7.75 | $11,307.20 | (2%) 70.56K to 69.1K | |
| 02-Dec-22 8:00 PM View: | Williams Richard Thomas Chief Medical Officer | Kinnate Biopharma Inc. (KNTE) | 01-Dec-22 | Payment of Exercise | 541 | $7.75 | $4,192.75 | (< 1%) 68.47K to 67.93K | |
| 02-Dec-22 8:00 PM View: | Meltz Mark A COO General Counsel Secretary | Kinnate Biopharma Inc. (KNTE) | 01-Dec-22 | Payment of Exercise | 541 | $7.75 | $4,192.75 | (2%) 28.46K to 27.92K | |
| 02-Sep-22 5:00 PM View: | Williams Richard Thomas Chief Medical Officer | Kinnate Biopharma Inc. (KNTE) | 01-Sep-22 | Grant | 25,000 | -- | -- | 58% 43.47K to 68.47K | |
| 02-Sep-22 5:00 PM View: | Meltz Mark A COO General Counsel Secretary | Kinnate Biopharma Inc. (KNTE) | 01-Sep-22 | Grant | 25,000 | -- | -- | 722% 3.46K to 28.46K | |
| 02-Sep-22 5:00 PM View: | Krishnamohan Neha Chief Financial Officer | Kinnate Biopharma Inc. (KNTE) | 01-Sep-22 | Grant | 67,500 | -- | -- | 4455% 1.51K to 69.02K | |
| 15-Mar-22 5:01 PM View: | Williams Richard Thomas Chief Medical Officer | Kinnate Biopharma Inc. (KNTE) | 14-Mar-22 | Purchase | 25,000 | $8.37 | $209,250.00 | 144% 17.33K to 42.33K | |
| 15-Mar-22 5:01 PM View: | Williams Richard Thomas Chief Medical Officer | Kinnate Biopharma Inc. (KNTE) | 11-Mar-22 | Private Purchase | 15,000 | $8.64 | $129,600.00 | 643% 2.33K to 17.33K | |
| 15-Feb-22 9:42 PM View: | Orbimed Advisors LLC Director | Kinnate Biopharma Inc. (KNTE) | 15-Feb-22 | Purchase | 9,000 | $9.96 | $89,640.00 | < 1% 4.03M to 4.04M | |
| 15-Feb-22 9:51 PM View: | Gordon Carl L Director | Kinnate Biopharma Inc. (KNTE) | 15-Feb-22 | Purchase Duplicate | 9,000 | $9.96 | $89,640.00 | < 1% 4.03M to 4.04M | |
| 15-Feb-22 9:42 PM View: | Orbimed Advisors LLC Director | Kinnate Biopharma Inc. (KNTE) | 14-Feb-22 | Purchase | 30,700 | $9.95 | $305,486.00 | < 1% 4.0M to 4.03M |
